EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome

Glenn E. Palomaki, Monica R. McClain, Stephanie Melillo, Heather L. Hampel, Stephen N. Thibodeau

Research output: Contribution to journalReview article

334 Scopus citations

Abstract

Funding for this study was provided by the National Office of Public Health Genomics, Centers for Disease Control and Prevention, through a contract (200-2003-01396-0128) with McK- ing Consulting Corporation, Inc. We thank the members of the Technical Evaluation Panel, including EGAPP Working Group members Celia I. Kaye, MD, University of Colorado at Denver and Health Sciences Center; Margaret Piper, PhD, MPH, Blue Cross/Blue Shield Association Technology Evaluation Center; James E. Haddow, MD, Women and Infants Hospital, The Warren Alpert School of Medicine at Brown University; Sue Richards, PhD, Oregon Health and Science University; and Linda A. Bradley, PhD, National Office of Public Health Genomics, CDC, who provided guidance and comments on drafts of this manuscript. We also thank Scott D. Grosse, PhD, National Center on Birth Defects and Developmental Disabilities, CDC and Mercy Mvundura, PhD, National Office of Public Health Genomics, CDC, for their helpful comments regarding the economic analyses.

Original languageEnglish (US)
Pages (from-to)42-65
Number of pages24
JournalGenetics in Medicine
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2009

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome'. Together they form a unique fingerprint.

  • Cite this